Study #2019-1001
A Phase I Study of NBTXR3 activated by Radiotherapy for Locally Advanced or Borderline-Resectable Pancreatic Ductal Adenocarcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Description
To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Borderline Resectable Pancreatic Adenocarcinoma;Locally Advanced Pancreatic Ductal Adenocarcinoma;Resectable Pancreatic Ductal Adenocarcinoma;Stage III Pancreatic Cancer AJCC v8
Study phase:
Phase I
Physician name:
Eugene Koay
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.